Compass Therapeutics stock price target maintained at $6 by Stifel

Stifel reiterated its Buy rating and $6.00 price target on Compass Therapeutics despite CMPX trading at $1.31, down 81% from its 52-week high and 65% over six months. The firm sees value in tovecimig's potential in second-line biliary tract cancer, citing feedback that the drug may reduce progression risk by more than 50%, though FDA full-approval feedback has reduced commercialization visibility. Compass plans to reengage the FDA on accelerated approval and submit a biologics license application in H1 2027; its enterprise value is below $100 million, while cash burn remains a key risk despite a 11.22 current ratio.

Analysis

CMPX is trading as a financing-and-regulatory option rather than on near-term operating fundamentals. The key valuation disconnect is not whether tovecimig has activity, but whether the company can secure a lower-evidence regulatory path before needing to fund a longer confirmatory route; failure would convert the apparent sub-$100M EV discount into dilution risk. The current ratio is not a runway metric, so the next filing should be reviewed for quarterly operating burn, restricted cash, and explicit financing horizon before treating the balance sheet as a cushion.

Near-term upside is likely constrained because a favorable re-engagement with FDA may still only clarify process rather than create an approval-ready asset. A credible accelerated-approval dialogue or a clean earlier-stage readout in 4Q26 could re-rate shares sharply given the depressed base, but the market will demand durable response, safety, and a commercially viable trial design—not favorable KOL commentary. Conversely, any indication that FDA requires additional randomized survival evidence would likely push commercialization beyond the stated filing window and force material multiple compression.

Consensus may be over-weighting the headline price target and under-weighting the value of timing: a 1H27 filing has limited present value if cash needs pull forward into 2026-27. The more attractive setup is therefore event-driven, with position size determined by confirmed runway and regulatory meeting language, rather than a directional bet based on a sell-side valuation framework.

Key Decisions for Investors

• Keep CMPX on a 4Q26 catalyst watchlist rather than initiate a core position now; require disclosure supporting cash runway through at least the planned 1H27 filing before underwriting a long.
• For a high-risk biotech sleeve, consider a small CMPX starter only after FDA re-engagement confirms an accelerated-approval path or after a data release validates durable benefit; target a 2-3x upside scenario versus a likely 50%+ downside if the program shifts to a longer confirmatory requirement.
• Do not use listed options absent confirmation of adequate open interest and spreads; equity sizing is preferable for this binary setup given likely liquidity limitations.
• Exit or avoid a long if management guidance implies an equity raise before the next major clinical/regulatory catalyst, or if FDA communication requires additional randomized survival follow-up; either outcome would materially weaken the asymmetric valuation case.